P-193 - EFFECT OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB ON SUBSTRATES FOR OATP1B1/3, BCRP AND CYP2B6 IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS.
J. Williams1, M. Reddy2, Y. Zhang2, L. Del Frari3, K. Matschke4, K. Litwiler2; 1Pfizer Inc., San Diego, CA, USA, 2Pfizer Inc., Boulder, CO, USA, 3Pierre Fabre Medicament, Toulouse, France, 4Pfizer Inc., Collegeville, PA, USA.
.png)